HaemaLogiX Raises $10M in Funding
- haemaLogiX, a Sydney, Australia-based biotech company, raised $10M in funding
- The round was led by Platinum Asset Management via its Platinum International Health Care Fund
- The company intends to use the funds to support manufacturing of the next batch of the Kappa antibody plus the conduct of a higher dose, 30mg/kg
- The company provides immuno-oncology and immune therapies for patients with blood cancers
- The company is focused on the development and commercialization of monoclonal antibodies (KappaMab) for the potential treatment of multiple myeloma (and potentially other blood cancers)
- Final results from the Phase IIb clinical trial are expected to be published in late 2021
